Cell Bank of Epstein Barr Virus Specific Cytotoxic T Lymphocytes

Nantes University Hospital (NUH)

Status and phase

Unknown

Phase 1

Conditions

EBV Associated Lymphoma

Treatments

Biological: Injection of allogenic CTL EBV specific

Study type

Interventional

Funder types

Other

Identifiers

NCT01823718

04/7-M

Details and patient eligibility

About

Patients patients enrolled in this study have a Lymphoma caused by EBV (after bone marrow transplantation, organ transplantation or patient immunodeficient.

They will receive one to three injections of allogenic CTL specific EBV.

The purpose of this study is to ensure that these injections can not cause a GVH and to study what the side effects are and to see whether this therapy might help patients with Lymphoma.

Immunological monitoring will also be studied.

Enrollment

18 estimated patients

Sex

All

Ages

12+ months old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female, without immunosuppressed organ transplant or immunocompromised and who received a kidney transplant, or kidney-pancreas, or heart or lung or heart-lung, or liver, or cells hematopoietic stem cells, and has given its consent
Aged 18 to 75 years Children aged more than 12 months,
PS <4
Viral load determined EBV
Life expectancy> 1 month
Patient typed for HLA DP DQ DR ABC
Patients with lymphoma in the immunosuppressed associated with EBV and failure, partial response (<50%) or relapsed after treatment with monoclonal antibodies and / or chemotherapy completed for at least three weeks. Patients with partial response may have a PET scan to confirm the lack of response.
Patient with a measurable mass to assess the response or bone marrow infiltration and / or measurable blood and having frozen tumor material or having a repeat biopsy.
Availability of a CTL matching at least two HLA or one HLA after validation experts with tumor cells
test de cytotoxicity negative

Exclusion criteria

Patient Pregnant or lactating
Concurrent infection with HIV
EBV negative lymphomas
If acute GVHD> grade II J-1 before injection (case grafts CSH)
Treatment of molecules in pre-marketing authorization older than 21 days
No matching at least two CTL HLA or non expert validation for the use of CTL with HLA sharing a single tumor
Test of cytotoxicity positive
Lack of recognition of tumor cells when available